Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study

BACKGROUND: Bendamustine was approved in China on May 26th, 2019 by the National Medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL). The current study was the registration trial and the first reported evaluation of the efficacy, safety, and pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuan-Kai, Hong, Xiao-Nan, Yang, Jian-Liang, Xu, Wei, Huang, Hui-Qiang, Xiao, Xiu-Bin, Zhu, Jun, Zhou, Dao-Bin, Han, Xiao-Hong, Wu, Jian-Qiu, Zhang, Ming-Zhi, Jin, Jie, Ke, Xiao-Yan, Li, Wei, Wu, De-Pei, Yang, Shen-Miao, Du, Xin, Jia, Yong-Qian, Liu, Ai-Chun, Liu, Dai-Hong, Shen, Zhi-Xiang, Zhang, Lian-Sheng, James, Leonard, Hellriegel, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183773/
https://www.ncbi.nlm.nih.gov/pubmed/33967195
http://dx.doi.org/10.1097/CM9.0000000000001463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183773/
https://www.ncbi.nlm.nih.gov/pubmed/33967195
http://dx.doi.org/10.1097/CM9.0000000000001463

Ejemplares similares